Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIQ263)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Monoglyceride lipase (MAGL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABX-1431	DM9SYVJ	Neuropathic pain	8E43.0	Phase 1	[2]
PMID29053063-Compound-11d	DMDRK68	N. A.	N. A.	Patented	[1]
Piperazine carbamic compound 1	DMZSYU4	N. A.	N. A.	Patented	[1]
Piperazine carbamic compound 2	DMMQ0ZO	N. A.	N. A.	Patented	[1]
Pyrazole derivative 82	DMETCI3	N. A.	N. A.	Patented	[1]
Pyrazole derivative 81	DMWT437	N. A.	N. A.	Patented	[1]
PMID29053063-Compound-15	DM07U5R	N. A.	N. A.	Patented	[1]
Pyrazole derivative 80	DMQ3TGM	N. A.	N. A.	Patented	[1]
Carbamide derivative 24	DMD6Y73	N. A.	N. A.	Patented	[1]
Piperazine carbamic compound 4	DMKZUO4	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)